课题基金 / 基金详情

LY303366 DOSE RANGING EFFICACY AND SAFETY STUDY IN ORAL CANDIDIASIS

LY303366 DOSE RANGING EFFICACY AND SAFETY STUDY IN ORAL CANDIDIASIS
LY303366 口腔念珠菌病的剂量范围疗效和安全性研究
批准号:
6117806
负责人:
JOSEPH WHEAT
金额:
$1.7万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-12-01 至 1999-11-30

项目摘要

项目成果

JOSEPH WHEAT的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This is a randomized, double-blind, multicenter evaluation of the safety and efficacy of three orally administered 1-week dosage regimens of LY303366 and a reference regimen of orally administered fluconazole for 2 weeks in the treatment of patients with oral candidiasis co-infected with HIV. Approximately 160 patients will be randomized to provide approximately 128 patients who qualify for efficacy analysis. Patients who have met the entry criteria and have signed and informed consent document will be randomly assigned to on of the four treatmen groups. The posttherapy follow-up period will b 3 or 2 weeks, if randomized to an LY303366 regimen for fluconazole regimen, respectivly. An interim analysis is planned when data from at least 48 qualified patients (approximatley 12 patients in each regimen) have been validated. One or more treatment regimens may be deleted following the interim analyses. Deletion of a treatment regimen will not affect patients who are already being treated with that regimen.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DAPSONE AND ATOVAQUONE FOR PROPHYLAXIS AGAINST PCP
THALIDOMIDE FOR TREATMENT OF ORAL/ESOPHAGEAL APHTHYOUS ULCERS AND HIV VIREMIA
AMBISOME VS AMPHOTERICIN B FOLLOWED BY FLUCONAZOLE IN TREATMENT OF MENINGITIS
CS96 209 SCH56592 VERSUS FLUCONAZOLE IN THE TREATMENT OF OROPHARYNGEAL CANDIDA
海外基金